Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV InfectionElisabetta Degasperi, Pietro Lampertico, Roberta D’Ambrosio et al.|Clinical Gastroenterology and Hepatology|2018Cited by 114
Direct-acting antivirals: the endgame for hepatitis C?Roberta D’Ambrosio, Alessio Aghemo, Elisabetta Degasperi et al.|Current Opinion in Virology|2017Cited by 97
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysisVíctor Sapena, María Reig, Marco Enea et al.|Gut|2021Cited by 96
Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis CAlessio Aghemo, Massimo Colombo, Gian Maria Prati et al.|Hepatology|2012Cited by 94
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVRRoberta D’Ambrosio, Pietro Lampertico, Elisabetta Degasperi et al.|Journal of Hepatology|2021Cited by 75